This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Growth impairment shows an age-dependent pattern in boys with chronic kidney disease
The impact of chronological age on longitudinal body growth from early childhood through adolescence using detailed anthropometric methods has not yet been studied in children with chronic kidney disease ( CKD ) . We have evaluated growth failure by measuring four components of linear growth : body height ( HT ) , sitting height ( SHT ) , arm length ( AL ) and leg length ( LL ) . Data were prospect ively collected for up to 7 years on 190 boys ( 3–21 years old ) with congenital or hereditary CKD ( all had developed at least stage 2 CKD by the age of 10 years ) . Patients showed the most severe growth failure in early childhood , followed by an acceleration in growth in pre-puberty , a slowing-down of growth at puberty , as expected , and thereafter a late speeding-up of growth until early adulthood . This pattern was observed irrespective of the degree of CKD and different treatment modalities , such as conservative treatment , recombinant human growth hormone ( rhGH ) therapy or transplantation . LL showed the most dynamic growth changes of all the parameters evaluated and emerged as the best indicator of statural growth in children with CKD . A specific age-dependent pattern of physical growth was identified in pediatric male CKD patients . This growth pattern should be considered in the evaluation of individual growth and the assessment of treatment efficacy such as rhGH therapy
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .